AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Amgen launches an AbbVie Humira biosimilar in the US
January 31, 2023 1:56 PM ESTAfter a dip earlier in the session, AbbVie (NYSE: ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ: AMGN) announcing AMJEVITA, a biosimilar to Humira, is now available in the United States.
AMJEVITA was the first biosimilar to AbbVie's Humira approved by the U.S. Food and Drug Administration and is now available in the U.S. at a list price 5% below the current Humira list... More
